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ABSTRACT
New genetic and environmental studies of Parkinson’s disease have revealed early 
problems in synaptic function and connectivity indicating that axonal impairment may 
be an important hallmark in this disorder. Since many studies suggest that axonal 
dysfunction precedes cell body loss, it is critical to target axons with treatments aimed 
at preserving “connectivity” as well as to develop and verify “biomarkers” with which to 
assess disease progression and drug efficacy.
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  Parkinson’s disease (PD) is a common neuro-
degenerative disorder with at least one million 
people in the United States and six million world-
wide being affected. The clinical symptoms of PD, 
tremor, rigidity and bradykinesia, primarily arise 
from the loss of dopaminergic cells in the sub-
stantia nigra pars compacta. Characteristic path-
ological changes include decreased mitochondrial 
complex I activity and increased indices of oxidative 
stress as well as the presence of intracellular and 
axonal deposits called Lewy bodies and Lewy 
neurites, respectively (Samii et al., 2004). Although 
the etiology of PD remains unknown, both genetic 
and environmental factors appear to play a role. 
A number of genes associated with familial PD 
have been identified (e.g. a-synuclein, parkin, DJ-1, 
PINK1, LRRK2, UCHL1, ATP13A2) demonstrating 
that molecular mechanisms underlying PD are com-
plex and likely to be heterogeneous (Schapira et 
al., 2009; Westerlund et al., 2010). In addition, 
exposure to toxins such as N-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) or its active de-
rivative, MPP＋, results in a disorder that mimics 
many aspects of this disease (Westerlund et al., 
2010).
  Most knowledge about the molecular mechanisms 
underlying PD has come from postmortem tissue 
studies as well as the genetic associations and 
environmental toxins which mimic the disorder 
(Schapira et al., 2009; Westerlund et al., 2010). In 
general, these studies support the view that in PD, 
dopaminergic neurons die via programmed cell 
death or apoptosis. Thus therapeutic strategies 
aimed at halting the underlying causes of cell loss 
in PD have targeted apoptotic pathways with some 
success, at least in animal models. Unfortunately, 
there is little clinical evidence to show that blocking 
cell death is neuroprotective (Waldmeier et al., 
2006). These results underscore the need for bro-
adening the models of PD pathogenesis. Fur-
thermore, it is increasingly apparent that preserving 
critical circuits can only be achieved by “staying 
connected”.  
  Recently, ultrastructural, physiological, and gene-
tic studies have revealed early abnormalities in 
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Fig. 1. Key features of axonal transport: cargos, tracks and motor proteins.
synaptic function and connectivity in PD. Thus, 
mounting evidence indicates that axonal dysfunction 
may be an important hallmark in PD, one that 
unifies the many disparate models (Hilliard, 2009; 
Morfini et al., 2009). 
  How does impaired axonal transport lead to axon 
pathology? Neurons are the most highly polarized 
of vertebrate cells with axons extending up to 
10,000 times the width of their cell bodies. Thus, 
neurons depend upon efficient transport systems to 
get “cargos” (proteins, vesicles, and other organe-
lles) where they need to go. Cargos move along 
tracks of microtubules with the help of specialized 
proteins. For instance, cargos are transported in the 
anterograde direction by kinesin motor proteins 
while cargos returning to the cell body are largely 
transported by dynein motors (Cai and Sheng, 
2009). When either process is disrupted, cargos 
can accumulate leading to protein aggregation, the 
sequestration of cellular factors and organelles, 
activation of cell stress signaling cascades, dis-
ruption of the tracks themselves and ultimately, 
axonal degeneration. Defective axonal transport will 
also lead to the loss of new material and/or 
vesicles at the distal axon, the loss of neurotropic 
signaling, the failure to degrade defective proteins 
and potentially the activation of programmed cell 
death pathways. Finally, even very subtle changes 
in axon transport may lead to the re-distribution of 
important organelles such as mitochondria with an 
ensuing loss of energy and consequently disruption 
of energy-driven processes such as synaptic func-
tion, movement of other cargoes, etc. (Cai and 
Sheng, 2009). A model of some of these key 
features is shown in Fig. 1.  
  What is the evidence that defective axonal 
transport plays a role in PD? First, there is 
widespread axonal pathology from the earliest 
stages of the disorder suggesting that axonal 
function is impaired (Braak et al., 2004). Moreover, 
in patient, non-human primate and animal models 
of PD, the loss of axons appears to precede the 
loss of cell bodies (Dauer and Przedborski, 2003). 
For example, the onset of symptoms in patients 
appears after most of the axonal dopamine in the 
striatum has been depleted (70∼80%) and about 
half of the nigral dopamine-producing cells have 
died (Bernheimer et al., 1973). Also, the appear-
ance of α-synuclein-positive Lewy neurites almost 
always precedes that of Lewy Bodies (Braak et al., 
2004; Orimo et al., 2008). These observations have 
led to the hypothesis that nigral neurons de-
generate through a “dying back” axonopathy in 
which degeneration begins in the distal axon and 
proceeds over weeks or months towards the cell 
body (Raff et al., 2002).
  Second, mutations in the PD-linked Leucine-Rich 
Repeat Kinase 2 (LRRK2) gene, which represent 
the most common genetic cause for familial (6%) 
and idiopathic (1∼2%) PD is also associated with 
aggregated axonal α-synuclein as well as with tau 
pathology (Ballatore et al., 2007). Knockdown of 
LRRK2 or introduction of “kinase-dead” constructs 
leads to long, highly branched neuritic processes 
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whereas constructs with increased kinase activity 
exhibit very short simple processes in neuronal 
cultures or transduced nigrostriatal models (Mac-
Leod et al., 2006). Moreover, transgenic mice ex-
pressing the PD-linked mutation LRRK2 (R1441G) 
recapitulate key features of PD itself including 
motoric, neurochemical and pathological features (Li 
et al., 2009). Importantly, these animals exhibit an 
early, progressive decline in dopaminergic terminal 
fields with a more than 8-fold increase in dystrophic 
processes and abnormal axonal swellings (Li et al., 
2009). Thus, these data also support the idea that 
impaired axonal transport plays an early, pivotal 
role in LRRK2-associated PD. 
  Third, α-synuclein-positive Lewy neurites precede 
Lewy bodies in the brain (Braak et al., 2004) as 
well as in the cardiac sympathetic nervous system 
(Orimo et al., 2008). Specifically α-synuclein ag-
gregates appear first in distal axons then as these 
regress, aggregates accumulate in more proximal 
axons and subsequently cell bodies (Braak et al., 
2004; Orimo et al., 2008). Conceivably, this early 
chronology mirrors the pathological mechanism 
associated with PD. Additionally, α-synuclein mu-
tants. accumulate in the cell soma when over-
expressed in cortical neurons, suggesting reduced 
axonal transport as well (Saha et al., 2004). Recent 
studies examining protein domains associated with 
transport indicate that those regions involved in 
membrane binding decreased the number of α
-synuclein particles present in hippocampal sy-
napses (Yang et al., 2010). Authors speculate that 
α-synuclein might function as a scaffolding protein 
linking membranous cargoes with microtubule-de-
pendent axonal transport (Yang et al., 2010) 
  Fourth, genetic mutations in the PD-linked genes, 
Parkin, an E3 ligase, and PINK1 (PTEN-induced 
putative kinase 1 protein) a mitochondrially-targeted 
kinase, have been shown to regulate mitochondrial 
fission/fusion machinery and alter axonal transport 
(Lu, 2009; Bueler, 2010). For example, mitochon-
dria are not only transported up and down the axon 
they also undergo dynamic interconversion events 
in which two mitochondria fuse to form a long 
tubular structure (fusion) or a single mitochondria 
splits in two (fission). Fusion/fission processes are 
thought to be intimately involved in mitochondrial 
transport since 1) mutations associated with Drp1, a 
fusion promoting gene, impair axonal transport (Lu, 
2009); 2) fused, elongated mitochondria are less 
mobile then short, vesicular structures (Cai and 
Sheng, 2009); and 3) fission generates healthy 
mitochondria that are transported down the axon 
whereas damaged, dysfunctional mitochondria are 
sent back to the cell body for repair by fusion or 
degraded via mitophagy (Miller and Sheetz, 2005). 
Very recent data indicate that PINK 1 is selectively 
stabilized on depolarized mitochondrial membranes. 
This in turn acts as a signal for Parkin recruitment 
which tags Pink-positive, depolarized mitochondria 
for destruction via autophagy (i.e. mitophagy; Na-
rendra et al., 2010). PINK1 can also form a 
complex with the key mitochondrial transport 
proteins, Miro and Milton (Weihofen et al., 2009). 
Taken together these data suggest that PINK1/ 
Parkin PD-linked mutations lead to impaired mito-
chondrial dynamics resulting in altered transport, 
distribution and loss of synaptic function.  
  Fifth, environmental toxins known to mimic PD 
such as rotenone and MPTP or MPP＋, not only 
inhibit mitochondrial Complex I activity, but also de- 
polymerize microtubules which take on a beaded, 
broken appearance leading to axon fragmentation 
(Cappelletti et al., 2005; Ren et al., 2005). This 
might be due to a direct interaction or indirectly as 
a consequence of Complex I inhibition resulting in 
the loss of ATP and increased oxidative stress 
(Cappelletti et al., 2005; Ren et al., 2005). In either 
case, loss of microtubule integrity would clearly lead 
to axonal degeneration (Fig. 1). 
  Sixth, recent data suggest that the Wallerian 
degeneration slow fusion protein (WldS) can delay 
axonal degeneration about 10-fold from a wide 
variety of genetic and toxin-inducing stimuli in vivo 
and in vitro. WldS is a chimeric protein composed of 
the N-terminal 70 amino acids of the ubiquitination 
factor Ube4b followed by a 18 amino acid linker 
region and the entire sequence of Nmnat1, a key 
enzyme in the biosynthesis of NAD＋ (Mack et al., 
2001). Most studies suggest that catalytically active 
Nmnat1 is necessary for axonal protection although 
it is unclear whether increased NAD＋ is responsible 
(Sasaki et al., 2009). Despite WldS being primarily 
localized in the nucleus, subcellular localization 
studies have found substantial amounts of WldS 
within the mitochondrial matrix where it may en-
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hance ATP synthesis (Yahata et al., 2009), prevent 
free radical formation (Press and Milbrandt, 2009), 
or maintain mitochondrial membrane potential (Ike-
gami and Koike, 2003). Data from this lab has 
shown that in the mouse MPTP model, the WldS 
gene product enhances survival, prevents nigro-
striatal axon degeneration, and attenuates neuro-
transmitter loss but does not rescue cell bodies 
(Hasbani and O’Malley, 2006). Despite this striking 
terminal field preservation, how WldS prevents 
axonal dysfunction is unknown but may be related 
to its effects on mitochondrial function. 
  Finally results using the isolated squid axoplasm 
model support the notion that MPP＋ directly inhibits 
fast axonal transport independent of mitochondria 
effects (Morfini et al., 2009). Specifically, MPP＋ 
increases retrograde trafficking of organelles in a 
PKCδ, caspase 3-dependent process. This in turn 
leads to a loss of appropriate neurotransmission 
and failure to generate post synaptic responses 
(Morfini et al., 2009). Taken together, these data 
provide direct evidence that the PD-mimetic, MPP＋ 
rapidly affects critical axonal processes. Moreover, 
using compartmented chambers and dopaminergic 
neurons derived from genetically altered animals 
expressing targeted GFP, we have been able to 
show that, like the squid giant axon, MPP＋ affects 
axonal trafficking (Unpublished results). 
  Taken together, results from both environmental 
and genetic factors linked to PD support an early, 
critical role for axonal impairment in this disorder. 
Therefore, it is critical to target new drugs to axons 
in order to preserve “connectivity”. At the very least, 
efforts to delay axonal dysfunction may push back 
the disease clock allowing those afflicted to main-
tain an improved quality of life. Ultimately, thera-
peutics targeted towards both the axon and the cell 
body may provide the most efficacious treatment of 
all.
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